Three linear antigenic regions on the N protein from human respiratory syncytial virus (RSV) subgroup A (strain A2) were identified by using peptides which reacted in ELISA with sera from humans with recent or previous RSV infection. The determinants were localized within three hydrophilic regions of the protein: Thrll to Gly30 (N3 peptide), Ser231 to Ala~50 (N25 peptide) and Thr3v 1 to Leu391 (N39 peptide). The site represented by the N39 peptide reacted with four subgroup A-specific MAbs. There were minor variations in the amino acid epitope dependencies of each of these MAbs. Two additional antigenic regions Serl~ 1 to Arg150 and Alals ~ to Leu.~00, were represented by peptides that reacted with human convalescent sera, but these peptides did not differentiate between acute and convalescent sera from RSV-infected humans. Rabbit hyperimmune sera raised against selected peptides specifically precipitated different forms of the N protein from a nucleocapsidcontaining homogenate derived from extracts of RSV-(subgroup A and/or B)-infected 35S-labelled cells in a radioimmuneprecipitation assay (RIPA); the sera were also used to demonstrate RSV infection in cells by immunofluorescent assay (IFA). Anti-N3 peptide sera precipitated N41, the full-length (M r 41000) form of N protein, in a RIPA done on a soluble protein pool. Anti-N39 (C-terminal region) peptide sera precipitated both forms, suggesting that N3s (M r 38 000) is an N-terminally truncated (probably at position Tyr23 located inside the N3 peptide linear antigenic region) form of N~l protein.
Introduction
Respiratory syncytial virus (RSV) is a negative singlestranded enveloped RNA virus belonging to the genus Pneumovirus in the family Paramyxoviridae. It is the single most important viral agent causing severe lower respiratory tract disease (bronchiolitis and pneumonia) in infants and children (McIntosh & Chanock, 1985) . The amino acid sequences of individual RSV proteins have been deduced from the nucleotide sequences of their corresponding genes. This information has allowed a representation of potential T cell and B cell epitopes of the proteins by use of synthetic peptides. Characterization of antigenic and immunogenic properties of such peptides can increase our understanding of RSV immunobiology.
The nucleoprotein (N) of RSV together with phosphoprotein (P), large (L) proteins and viral genomic RNA make up the nucleocapsid core of the virion (Collins, 1991) , the site of the transcription-replication complex * Author for correspondence. Fax +46 8 330744.
of the virus (Barik, 1992; Huang et al., 1993) . Studies of other negative-stranded viruses (Bishop et al., 1971) , for example vesicular stomatitis virus (VSV) (reviewed by Banerjee & Barik, 1992) , have defined a multifunctional role for the nucleoprotein in transcription-replication. In order to understand the role of different parts of RSV N protein in these functions, a need exists for more data on the structure and function of the N protein and its antigenic determinants (Ward et al., 1983; Collins, 1991) . The aim of our study was to identify antigenic and immunogenic regions on the RSV N protein and to map epitopes within these sites at the level of individual amino acids.
Immunodominant epitopes may be involved in protein-protein interactions within protein complexes, as in the case of the glycoprotein complex of human immunodeficiency virus (HIV) (Neurath et al., 1992) . Peptides that mimic VSV P protein sequences or anti-N protein sera that interfere with the viral transcriptionreplication process have been reported (Yamashita & Kawai, 1990; Hill & Summers, 1982) . Thus peptides, anti-peptide animal sera and MAbs can be used for immunochemical characterization of viruses (Norrby et 0001-2752 0001- © 1995 0001- SGM al., 1987 Akerlind-Stopner et al., 1990) and may be useful tools for structural-functional studies of the replicative complex of RSV.
Recently we reported similar studies of the RSVP protein (Leonov et al., 1994) . In the present study, we identified three immunodominant linear antigenic regions by use of synthetic overlapping peptides representing the RSV N protein. Peptides that reacted with a panel of 20 RSV-positive sera derived from convalescing patients and 14 paired sera from RSV-infected patients were identified. Linear antigenic sites were localized within three hydrophilic regions of the N protein: Thrll to Gly3o (N3 peptide), Ser231 to Ala250 (N25) and Thr371 to Leu391 (N39). The site represented by peptide N39 reacted with four subgroup A-specific MAbs. Within this region the epitope dependence on individual amino acids was characterized. Rabbit hyperimmune sera raised against selected peptides specifically precipitated different forms of the N protein from RSV-infected 35S-labelled cell extracts in a radioimmunoprecipitation assay (RIPA) and indicated RSV infection in cells by immunofluorescent assay (IFA).
Methods
Virus. RSV prototype strain A2 (subgroup A) was passaged in Vero cells and stored at -70 °C before use.
Cells. Vero cells were grown in Eagle's MEM supplemented with 3 % fetal calf serum (FCS) that had been inactivated by heating at 56 °C for 30 min. Virus was passaged as described elsewhere (Akerlind et al., 1988) in nearly confluent monolayer cultures at 10 p.f.u./cell. At the time of inoculation the medium was changed to Eagle's MEM with 0.5 % FCS.
Peptides. The derived amino acid sequence of RSV strain A2 N protein (Galinski. 1991) was used for simultaneous multiple solid-phase peptide synthesis according to the method of Houghten (1985) . Peptide amides were synthesized by using t-Boc amino acids (Bachem) and pmethylbenzhydrylamine resin (Fluka) and cleaved by liquid hydrogen fluoride in a multi-vessel apparatus. The peptides demonstrated 55 97 % homogeneity, as tested by HPLC on a Nova-pak C1~ column (Waters Associates). Amino acid composition was confirmed by amino acid analysis. A Cys residue was coupled to the C-terminal end of those peptides which lacked this amino acid in their sequence to enable coupling to keyhole limpet haemocyanin (KLH) as described by Sambrook et al. (1989) .
MAbs. Antibodies specific for the N protein and, as a control, the P protein were used. One group of MAbs was produced using the Long strain of RSV, a prototypic strain of subgroup A (Mufson et al., 1985) . The following antibodies from this group were used: anti-NP antibodies for epitopes NP1 -C797, C3222 and B90 (subgroup A specific), NP2 B27, NP3 B37, NP4 -B130, NP5 -B131, and NP6 -B60 and B62: anti-P antibody for epitope P1 C771. Additional N protein-specific MAbs (also subgroup A specific) RSI02, RS104 and RS204C and P protein-specific MAbs RS201, RS202A, RS203 and RS205 were generated and characterized in the Department of Virology, University of Turku, Finland (Waris, 1992) . Another pair of MAbs, RSV4 and NC4, was produced by using RSV strain A2 (subgroup A)-infected cells as described by Obert & Beyer (1988) and was kindly made available for us. Additional MAbs that were generated against a subgroup B strain were 4-18 (anti-N) and 3-5 and 4-14 (both anti-P) (Gimenez et al., 1984) Animal sera. Rabbits were injected subcutaneously with 100 gg of KLH-conjugated synthetic peptides in Freund's complete adjuvant and then with two injections of the same peptides in Freund's incomplete adjuvant at 3 week intervals. The animals were bled 10 days after the last injection. Pre-immune and hyperimmune rabbit sera were collected and stored at -20 °C until use.
Human sera. Twenty RSV-positive sera (HCS), obtained from patients during their convalescence from RSV infection, and possessing clearly demonstrable titres of RSV IgG in enzyme immunoassays (EIA) based on RSV nucleocapsid antigen (Waris, 1992) and 16 paired human sera from patients with acute RSV infection primarily diagnosed by detection of antigen in nasopharyngeal aspirates were collected in the Department of Virology, University of Turku, Finland. One RSVnegative human serum (no. 92/2159, STII, from an infant 8 months old, and with a mean A492 value of < 0-2 at 1 : 100 dilution) in a peptide EL1SA was used as a negative control.
ELISA. ELISA with purified RSV antigen and peptides was performed as previously described (Akerlind-Stopner et al., 1990; Leonov et al., 1994) . The results were expressed either as A492 (mean of three determinations) or, for substituted peptide analogues, as the percentage of peptides binding. The titres of immune anti-peptide sera were calculated as the highest dilution that gave a mean A492 value that exceeded the "cut-off' value by more than 0.2 absorbance units, i.e. exceeded the mean of three determinations of A492 performed in wells with the same dilution of pre-immune sera plus two standard deviations.
The peptide competition ELISA was performed as described previously (Leonov et al., 1994) . Briefly, different concentrations (from 0I-20 gg/ml) of the competitive peptide together with a standardized dilution of MAb (giving 50 % of the maximum A49 ~) in ELISA dilution buffer were mixed, added to the wells pre-adsorbed with either homologous or heterologous peptide and allowed to react for 3 h at 37 °C. Competition ELISA between MAbs and HCS was performed in a similar manner using different dilutions (from 1:50-1 : 1000) of HCS as the competitive reactant. To analyse the peptide analogues in soluble form a competition ELISA based on a double antibody sandwich (DAS) protocol (Joisson & Van Regenmortel, 1991) was performed with some modifications. Briefly, different concentrations of competitive peptide analogues together with standardized (giving 50 % of the maximmn A492 value, i.e. without competitor) dilution of purified nncleocapsids were mixed and added to the wells pre-adsorbed with one of the affinity purified MAbs (either B90, C3222, RS102 or RS204C). Rabbit anti-N3 peptide serum was used as the source of the capture antibodies. Results were calculated as percentage inhibition compared to the value obtained with the original full-length N39 peptide (assumed to give 100% inhibition).
RIPA. The preparations of RIPA RSV antigen (from subgroup A, strain A2-and subgroup B, strain CH 1 g537-infected Vero cells) and the RIPA procedure were slightly modified from previously described methods (Leonov et al., 1994 
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* The amino acids (in bold) represent identified antigenic determinants containing epitopes (underlined). The amino acids positions in the original RSV strain A2 N protein sequence (Galinski, 1991) are indicated.
by Dounce homogenization and clarified samples were overlaid onto a two-step 20% (w/w)-60% (w/w) sucrose gradient. After centrifugation (90 min, 12 °C, 260000 g) the 'free' (FF) protein pool fraction from the top of the 20% sucrose and the 'nucleocapsid-associated' (NCF) protein pool fraction from the 20-60 % sucrose interface were sequentially collected by gentle aspiration and dissolved in lysis buffer (Leonov et al., 1994) ; after final centrifugation (13000 g) for 5 min the supernatant was used as RIPA antigen. A mixture ofprotease inhibitors (Protease inhibitors set), prepared according to the manufacturer (Boehringer Mannheim) was added to the samples at each step of RIPA antigen preparation. RIPA of these fractions was done as described previously (Leonov et al., 1994) .
IFA. IFA of acetone-fixed (-20 °C, 20 min) and formaldehyde-fixed (0.5 % in PBS, room temperature, 20 min) RSV (A2)-infected cells was done as previously described (Norrby et al., 1982) .
Computer analysis. Analysis of the secondary structure of RSVP protein was performed by use of the DNA Strider 1.1 computer program based on Kyt~Doolittle and Chou-Fasman algorithms.
Results

ELISA reactivity of late convalescent and paired human sera with peptides representing the RSV N protein
Thirty-nine 20-amino-acid-long peptides (with a 10 residue overlap) representing the complete amino acid sequence of the N protein of RSV (strain A2) were synthesized. Each of 20 HCS (from persons of different ages) was tested in ELISA with each of these N protein peptides (designated as Nn, where n is the peptide number). Peptides N3, N15, N20 and N25 (Table 1) reacted with all 20 HCS ('cut-off' A49 ~ value 0.2) and peptide N39 reacted with 17 HCS (Fig. I) . The other N protein peptides demonstrated little reactivity (data not shown). The ELISA reactivity values of each of 16 paired human sera (expressed as A492 convalescent sera:A492 acute sera at one given dilution = C/A ratio) with peptides N3, N15, N20, N25 and N39 (Fig. 2) confirmed their antigenic reactivity. Peptides N3, N25 and N39 exhibited more pronounced differences between convalescent and acute sera than did peptides N15 or N20 (Fig. 2) .
Reactivity of MAbs with peptides representing the RSV N pro tein
The complete collection of 39 peptides was tested in ELISA with anti-N protein MAbs, including four that were subgroup A-specific and 11 MAbs specific to both 
Characterization of amino acid dependencies of the epitopes with peptide analogues
To define the dependence on individual amino acids of epitopes recognized by different MAbs we synthesized substituted analogues of N39 peptide in which each amino acid (starting from the C-terminal Cys) of the original peptide sequence was substituted in turn by Gly. These N39 Gly-substituted analogues were tested in ELISA with RSV subgroup A-specific MAbs B90, C3222, RS102 and RS204C. All the amino acids in the stretch of residues Leu~82 to Glu390 were crucial (reduced binding of 50% and more) for MAb B90 to show reactivity with the corresponding peptide analogues (Fig.  3 a) . The reactivity of MAb C3222 showed dependence on this antigenic site and also somewhat on Lysa79 (reduced binding of 20%) (Fig. 3b) . A pronounced dependence on Lys379 (reduced binding of more than 50 %) and slight dependence on Gln381 (reduced binding of 20%) was found with MAb RS102 (Fig. 3c) . A few amino acids, Leu382 to Va1389, were important for interaction of MAb RS204C with these analogues (Fig.  3d) . Thus, the antigenic site represented by N39 contained at least four, and possibly more, distinct epitopes. To characterize the minimal epitope composition which reacted with each of these four MAbs, we tested a set of N39 truncated peptides (Fig. 4) . These shortened peptides revealed the need for the neighbouring amino acids Gln381 and Leu301 in order to maintain 100% binding of RS204C and B90, 60 % binding of C3222 and 48 % binding of RS102 compared with the original full-length N39 peptide. The peptide representing amino acid sequence Gln381 to Leu391 (N39T) was selected for evaluation of its immunogenic activity in rabbits (sera raised against N39T are referred to subsequently as R210 sera). Interestingly, removal of amino acid Gln38 ~ allowed the truncated peptide (Leu382 to Leu391) to be recognized only by RS204C and B90 (reactivity levels 95% and 65%, respectively). The reaction patterns of peptides (data not shown) were similar when they were studied in soluble form by use of a DAS assay. Table 1 .
Immunogenic properties of N protein peptides
Rabbit hyperimmune sera against peptides N3 (R205), N15 (R207), N20 (R208), N25 (R206), N39 (R201) and against the truncated analogue of the N39 peptide N39T (R210) were tested in an ELISA with homologous synthetic peptides and purified RSV subgroup A strain A2 (Table 2 ) and subgroup B strain CH18537 (data not shown). These sera demonstrated relatively high antipeptide antibody titres. However, the capacity of these sera to react with whole virus was variable: (i) the highest immunoreactivity was found with R205 antisera; (ii) relatively moderate reactivities were observed for R201, R210 and R206 sera; (iii) borderline antibody activities were found with R207 and R208 sera. The reactivity of the sera in IFA with subgroup A (strain A2) and subgroup B (strain CH18537)-infected Vero cells (data not shown) correlated with ELISA results employing whole virions. The reactivities of sera R207 and R208 were weak, but specific. Table 1 . Table 2 .
ELISA of rabbit anti-peptide sera immunoreactivity with different antigens
Titre of rabbit anti-peptide sera* R205 R207 R208 R206 R201 R210 Antigen (a-N3) (a-N15) (a-N20) (a-N25) (a-N39) (a-N39)t
Homologous peptide 62500 6400 12500 12500 25600 32000 RSV (A2) virions 25600 100 100 400 1600 1600 * Calculated as described (see Methods). ~ Short analogue of N39 peptide, i.e. Gln3s 1 to Leua91 (the amino acids positions in the original RSV strain A2 N protein sequence are as referred to in Table 1 ).
The capacity of the different anti-peptide sera to react with different conformational states of the nucleocapsid protein assumed to be represented in the FF and NCF fractions (see Methods) was assessed in a RIPA using as antigen protein fractions from 35S-labelled cells infected with subgroup A (strain A2) and subgroup B (strain CH18537) (data not shown). These assays (Fig. 5) demonstrated that antisera R205 (lane 1), R206 (lane 6), R201 (lane 5) and R210 (lane 4) precipitated 'N41' (the full-length form of the N protein, apparent Mr 41000) together with' Nas' (the truncated form of the N protein, apparent Mr 38000). R207 (Fig. 5, lane 2) and R208 (data not shown) weakly precipitated the same protein doublet from the NCF fraction and R205 (Fig. 5, lane 7) precipitated only N41 from the FF fraction. All other anti-peptide sera precipitated both N protein forms (as shown for R201, Fig. 5, lane 8) from the FF fraction. In addition, R201 and R210 co-precipitated from the same protein fraction protein bands of apparent M r 36000, which corresponds to the M r of mature P protein (Cash et al., 1979) . The bands of apparent M r 30000 were observed in precipitated immune complexes between anti-peptide sera or MAbs and the NCF fraction of RSV subgroup A strain A2-infected cells. All anti-peptide sera precipitated N4a together with N38 forms from the NCF fraction of CH18537-infected cells (data not shown).
Discussion
Five antigenic regions of the N protein (Table 1) were identified by use of 20 RSV HCS in an assay of the antigenicity of N-specific peptides. Tests with paired human sera (Fig. 2) confirmed the preferential immunoreactivity of three of the five sites, i.e. Thrll to Gly30 (N3 peptide), Ser2~ 1 to Ala250 (N25 peptide) and Thr372 to Leu39a (N39 peptide). One of the five sites, the C-terminal part represented by the N39 peptide was defined by the four subgroup A-specific MAbs (data not shown) in peptide screening by using a large panel of N proteinspecific MAbs (Mufson et al., 1985; Orvell et al., 1987;  
. Waris, 1992) . Deduced amino acid sequences of the Cterminal part of subgroup A-and B-derived N proteins (Amann et al., 1992) revealed two coupled amino acid differences, i.e. Asp3sG Asn3s 7 (subgroup A, strain A2) substituted for Glu3s ~ Asp3s7 (subgroup B, CH18537 strain). Analysis of amino acid dependencies of MAb reactivity (Fig. 4) showed that amino acids in both these positions are crucial for the reactivity of this epitope. The complete target site needed three to four amino acids on each side of these two amino acids. Some variation was found in the amino acid dependence of each of the different MAbs. These differences were related to differences in the abilities of the MAbs to precipitate Nspecific proteins in RIPAs and to give subgroup-specific immunofluorescence under different conditions (Mufson et al., 1985) . The N-terminal part (represented by peptide N3) of the N protein also was highly antigenic and immunogenic. The additional three linear sites identified in the more central part of the protein showed a weaker reactivity, except for the antigenic activities of the N15 (Ser13 a to Argl~0) and N20 (Ala~81 to Leu~oo), with late convalescent sera. Thus, the immunogenic activity of these sites may become expressed after maturation of immune response or after repeated infections. Our ELISA data (Figs 1 and 2 ) confirm earlier observations (McIntosh & Chanock, 1985; Collins, 1991 ; Ward et al., 1983) concerning the abundance of anti-N antibodies in sera from RSV-infected persons and revealed that the site mimicked by the N3 peptide is one of the major antibody response targets within the N protein. The high ELISA titre of anti-N3 sera (R205) ( Table 2 ) and strong precipitation of N41 and N3s forms in the RIPA suggested high availability of the corresponding N protein site in virions of RSV. Moderate ELISA reactivities of human convalescent and paired sera with peptides N25 and N39 correlated well with the capacity of anti-N39 (R201), anti-N39 truncated analogue (R210) and anti-N25 (R206) sera to identify the linear immunogenic site in the folded protein of whole virions (Table 2) . ELISA based on N3 (Fig. 2) as well as on a combination of N3 and N39 reacted more often with acute and convalescent phase RSV infection sera than N39, alone or in combination with N25. These findings should be further confirmed by using a larger panel of paired human sera. The shortest (Leu3s 2 to Leu391) analogue of the N39 peptide elicited RSV subgroup A-specific immune sera in animals as detected by IFA and RIPA (data not shown).
The site-specific reagents generated in this study can be employed for analysis of precursor-product relationships and/or protein-protein interactions (Yamashita & Kawai, 1990; Neurath et al., 1992; Barge et al., 1993; Ryan et al., 1993; Gombart et al., 1993) . Two different forms of N protein, i.e. N41 (M,. 41000) and N3s (M r 38000), were detected by RIPA with the nucleocapsidassociated protein fraction of RSV-infected cells (Cash et al., 1979) . One of these forms, N3,, was thought to be the truncated (by a chymotrypsin-like protease) form of mature full-length N41 protein. Our anti-peptide sera raised against the N-terminal end only precipitated the N41 polypeptide from the 'flee' protein fraction, whereas the corresponding anti-peptide serum against the Cterminal end precipitated both N41 and N38. This finding suggests that the latter protein is generated by Nterminal truncation of the N4x protein at one of the potential sites of action of the chymotrypsin-like protease(s) (e.g. Tyr23, producing a truncated polypeptide with an expected M r of 2800). Precipitation of both N41 and Nas from nucleocapsid-associated protein fractions by either anti-N or anti-C terminal peptide sera suggested strong interactions between N41 and N3s inside nucleocapsids in contrast to the 'free' protein pool. The exact role of this N38 form in RSV infection is unclear. The sensitivity of RSV N4~ (Cash et al., 1979) and influenza virus nuclear protein (NP) (Zhirnov & Bukrinskaya, 1984) to proteolysis suggests that this event is associated with structural or environmental changes to these polypeptides, one such change being incorporation into nucleocapsids or virions. Nucleocapsid dissociation-reassociation experiments (our unpublished data) have indicated that N41 and N3s without P protein can form complexes (or aggregates) with RNA which have buoyant densities corresponding to that of the mature functional nucleocapsids containing N, P, L and M proteins and viral RNA. Self-assembly of NP protein of Sendal virus into nucleocapsid-like particles was recently reported (Buchholz et al., 1993) . Although N~s protein incorporation by RSV nucleocapsids was low (Cash et al., 1979) , we have observed preferential coprecipitation of the N4~ form together with P protein by the anti-P MAbs (unpublished). The M protein was always found in P protein-containing nucleocapsids (unpublished). These findings prompt the following questions which are now being investigated: (i) does nascent N4a (after some maturation event, possibly in its C-terminal part) associate with the N38 polypeptide and RNA to produce nucleocapsid-like particles (which are probably not functional at this state) in the absence or presence of low concentrations of P protein; (ii) does a newly synthesized P protein associate with mature N4a or compete out part of N~s from N~I-N3s-RNA complexes; (iii) do these P-N protein complexes incorporate M and L polypeptides and viral RNA to form active transcription-replication complexes appearing as inclusion bodies (Norrby et al., 1970; Garcia et al., 1993) inside RSV-infected cells.
